CORT News and Press, Corcept Therapeutics Incorporated From 07/20/22

NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), Rollins, Inc. (NYSE: ROL), and Wo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2022 is likely to go down as one of the most challenging years for investors since 2008. Year-to-date, the S&P 500 is down more than 20%, while there is equal pain in the bond market due to inflation and a hawkish Fed...

88% technical buy signals and rising. 14 new highs and up 29.27% in the last month. Price targets as high as $35.00. The Chart of the Day belongs to the biotechnology company Corcept Therapeutics ( CORT ). I found the stock by sorting Barchart's Top Stocks to Own...

NEW YORK, July 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), Rollins, Inc. (NYSE: ROL), and Ta...

NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), and Corcept The...

Corcept Therapeutics ( NASDAQ: CORT ) has commenced a phase 3 study of relacorilant plus nab-paclitaxe l in platinum-resistant ovarian cancer. The study plans to enroll 360 women with recurrent, platinum-resistant ovarian cancer. They will be randomized to receive rela...

MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of ...

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Unity Software, Inc. (NYSE: U), Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), and Corcept Therap...

NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), and Cla...

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), and Corcept Therapeutics,...